Humacyte, Inc. (NASDAQ:HUMA) Q4 2023 Earnings Conference Call March 22, 2024 8:00 AM ET Company Participants Lauren Marek - Investor Relations, LifeSci Advisors Laura Niklason - President and Chief Executive Officer Dale Sander - Chief Financial Officer and Chief Corporate Development Officer Conference Call Participants Ryan Zimmerman - BTIG Kristen Kluska - Cantor Fitzgerald & Co. Joshua Jennings - TD Cowen Allison Bratzel - Piper Sandler Vernon Bernardino - H.C. Wainwright Operator Good morning, ladies a ...

Exhibit 99.1 -Raised approximately $43.1 million in net proceeds from public offering of common stock- -Conference call and live webcast at 8:00 a.m. ET today- DURHAM, N.C., March 22, 2024 – Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced financial results for the fourth quarter and year ended December 31, 2023 and highlighted recent corporate accomplishments in advancing the in ...

Humacyte, Inc. (NASDAQ:HUMA) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Lauren Marek - Investor Relations, LifeSci Advisors Laura Niklason - President and Chief Executive Officer Dale Sander - Chief Financial Officer and Chief Corporate Development Officer Conference Call Participants Suraj Kalia - Oppenheimer Bruce Jackson - The Benchmark Company Operator Good afternoon, ladies and gentlemen, and welcome to the Humacyte Third Quarter Results Conference Call. Currently ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________________________________________________________________________ FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to __ ...

Humacyte Inc. (NASDAQ:HUMA) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Company Participants Dr. Laura Niklason - President & CEO Dale Sander - CFO & Chief Corporate Development Officer Dr. Heather Prichard - COO Laura Marek - LifeSci Advisors, IR Conference Call Participants Ryan Zimmerman - BTIG Josh Jennings - TD Cowen Matthew O'Brien - Piper Sandler Suraj Kalia - Oppenheimer & Company Bruce Jackson - The Benchmark Company. Operator Good morning, ladies and gentlemen, and welcome to the H ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________________________________________________________________________ FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of incorporation or ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________________________________________________________________________ FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ ...

Humacyte Inc. (NASDAQ:HUMA) Q1 2023 Results Conference Call May 12, 2023 8:00 AM ET Company Participants Lauren Marek - LifeSci Advisors Laura Niklason - Founder, President, CEO and Director Dale Sander - CFO, Chief Corporate Development Officer and Treasurer Conference Call Participants Phil Dantoin - Piper Sandler Ryan Zimmerman - BTIG Joshua Jennings - TD Cowen Suraj Kalia - Oppenheimer & Company Bruce Jackson - Benchmark Company Operator Good morning, ladies and gentlemen, and welcome to the Humacyte Fi ...

Humacyte, Inc. (NASDAQ:HUMA) Q4 2022 Earnings Conference Call March 24, 2023 8:00 AM ET Company Participants Lauren Marek - LifeSci Advisors, Investor Relations Laura Niklason - President and Chief Executive Officer Dale Sander - Chief Financial Officer and Chief Corporate Development Officer Heather Prichard - Chief Operating Officer Conference Call Participants Ryan Zimmerman - BTIG Phillip Paul Dantoin - Piper Sandler Josh Jennings - TD Cowen Suraj Kalia - Oppenheimer Bruce Jackson - The Benchmark Compan ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ___________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39532 Humacyte, Inc. (Exact name of registrant as specified in its charter) ___________________________________ (State or o ...